Cargando…

AMACR amplification and overexpression in primary imatinib-naïve gastrointestinal stromal tumors: a driver of cell proliferation indicating adverse prognosis

Non-random gains of chromosome 5p have been observed in clinically aggressive gastrointestinal stromal tumors, whereas the driving oncogenes on 5p remain to be characterized. We used an integrative genomic and functional approach to identify amplified oncogenes on 5p and to evaluate the relevance of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chien-Feng, Chen, Li-Tzong, Lan, Jui, Chou, Fong-Fu, Lin, Ching-Yih, Chen, Yen-Yang, Chen, Tzu-Ju, Li, Shau-Hsuan, Yu, Shih-Chen, Fang, Fu-Ming, Tai, Hui-Chun, Huang, Hsuan-Ying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4294386/ https://www.ncbi.nlm.nih.gov/pubmed/25473890

Ejemplares similares

Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors
por: Li, Chien-Feng, et al.
Publicado: (2016)

Selection of aptamers for AMACR detection from DNA libraries with different primers
por: Yang, Deng-Kai, et al.
Publicado: (2018)

AMACR overexpression acts as a negative prognostic factor in oral squamous cell carcinoma
por: He, Hong-Lin, et al.
Publicado: (2018)

Hydroxysteroid 11-Beta Dehydrogenase 1 Overexpression with Copy-Number Gain and Missense Mutations in Primary Gastrointestinal Stromal Tumors
por: Li, Chien-Feng, et al.
Publicado: (2018)

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan
por: Ichinose, Yuichi, et al.
Publicado: (2022)

CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis
por: Wang, Yu-Hui, et al.
Publicado: (2015)

The expressions of AMACR and iNOS in prostate adenocarcinomas
por: Ozgur, Tumay, et al.
Publicado: (2013)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Urine Exosomal AMACR Is a Novel Biomarker for Prostate Cancer Detection at Initial Biopsy
por: Jin, Xin, et al.
Publicado: (2022)

PAK1 overexpression promotes myxofibrosarcoma angiogenesis through STAT5B-mediated CSF2 transactivation: clinical and therapeutic relevance of amplification and nuclear entry
por: Li, Chien-Feng, et al.
Publicado: (2023)

RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor
por: Gao, Xiaodong, et al.
Publicado: (2016)

Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate
por: Wu, Ting-Jung, et al.
Publicado: (2006)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Global expression of AMACR transcripts predicts risk for prostate cancer – a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate
por: Alinezhad, Saeid, et al.
Publicado: (2016)

Identification of Five Driver Gene Mutations in Patients with Treatment-Naïve Lung Adenocarcinoma in Taiwan
por: Hsu, Kuo-Hsuan, et al.
Publicado: (2015)

MTOR inhibition enhances NVP-AUY922-induced autophagy-mediated KIT degradation and cytotoxicity in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2014)

Serum Levels of Stromal Cell-Derived Factor-1α and Vascular Endothelial Growth Factor Predict Clinical Outcomes in Head and Neck Squamous Cell Carcinoma Patients Receiving TPF Induction Chemotherapy
por: Chen, Yen-Hao, et al.
Publicado: (2022)

Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance
por: Li, Chien-Feng, et al.
Publicado: (2014)

Molecular Comparison of Imatinib-Naïve and Resistant Gastrointestinal Stromal Tumors: Differentially Expressed microRNAs and mRNAs
por: Amirnasr, Azadeh, et al.
Publicado: (2019)

Neoadjuvant versus adjuvant imatinib in primary localized gastrointestinal stromal tumor
por: Ling, Jiayu, et al.
Publicado: (2023)

Heterogeneity of Metabolic Vulnerability in Imatinib-Resistant Gastrointestinal Stromal Tumor
por: Huang, Wen-Kuan, et al.
Publicado: (2020)

Effect of the imatinib treatment regimen on the postoperative prognosis of patients with high-risk gastrointestinal stromal tumors
por: Li, Yan-Shu, et al.
Publicado: (2019)

Preoperative imatinib for patients with primary unresectable or metastatic/recurrent gastrointestinal stromal tumor
por: Shen, Chaoyong, et al.
Publicado: (2014)

A study on the AMACR catalysed elimination reaction and its application to inhibitor testing
por: Yevglevskis, Maksims, et al.
Publicado: (2016)

Overexpression of UTX promotes tumor progression in Oral tongue squamous cell carcinoma patients receiving surgical resection: a case control study
por: Chen, Yen-Hao, et al.
Publicado: (2021)

The Radiation Dose to the Left Supraclavicular Fossa is Critical for Anastomotic Leak Following Esophagectomy – A Dosimetric Outcome Analysis
por: Chou, Shang-Yu, et al.
Publicado: (2022)

Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
por: Tang, Sumin, et al.
Publicado: (2017)

Prolonging Gastrointestinal-Stromal-Tumor-free life, an optimal suggestion of imatinib intervention ahead of operation
por: Yan, Lin-Hai, et al.
Publicado: (2018)

α-Methylacyl-CoA racemase (AMACR) serves as a prognostic biomarker for the early recurrence/metastasis of HCC
por: Xu, Bo, et al.
Publicado: (2014)

A-Methylacyl-CoA Racemase (AMACR) and Prostate-Cancer Risk: A Meta-Analysis of 4,385 Participants
por: Jiang, Ning, et al.
Publicado: (2013)

The Impact of Weight Loss during Chemoradiotherapy for Unresectable Esophageal Cancer: Real-World Results
por: Huang, Tzu-Ting, et al.
Publicado: (2022)

Identification of imatinib-resistant long non-coding RNAs in gastrointestinal stromal tumors
por: Yan, Jingyi, et al.
Publicado: (2019)

Ribophorin II Overexpression Is Associated with Poor Response to Induction Chemotherapy with Docetaxel, Cisplatin, and Fluorouracil in P16-Negative Locally Advanced Head and Neck Squamous Cell Carcinoma
por: Chen, Wei-Shan, et al.
Publicado: (2021)

PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: Integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival
por: Li, Chien-Feng, et al.
Publicado: (2017)

Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma
por: Lee, Hyunji, et al.
Publicado: (2020)

Diagnostic utility of triple antibody (AMACR, HMWCK and P63) stain in prostate neoplasm
por: Rathod, Santosh G., et al.
Publicado: (2019)

Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor
por: Wang, Gang, et al.
Publicado: (2021)

GSTT1 Copy Number Gain and ZNF Overexpression Are Predictors of Poor Response to Imatinib in Gastrointestinal Stromal Tumors
por: Lee, Eui Jin, et al.
Publicado: (2013)

Nox4 Overexpression as a Poor Prognostic Factor in Patients with Oral Tongue Squamous Cell Carcinoma Receiving Surgical Resection
por: Chen, Yen-Hao, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_sq4vkeftfjvpo0t9o0tser5nlp